Literature DB >> 18424828

Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the cat.

P J Mellor1, S Haugland, K C Smith, R M Powell, J Archer, T J Scase, E J Villiers, P E McNeil, C Nixon, C Knott, D Fournier, S Murphy, G A Polton, C Belford, A W Philbey, D J Argyle, M E Herrtage, M J Day.   

Abstract

Feline myeloma-related disorders (MRD) are rare neoplasms of plasma cells. The multistep transformation model of myeloma in humans is based on the premise that plasma cells undergo neoplastic transformation primarily within the intramedullary compartment and that over time they become poorly differentiated and metastasize to extramedullary locations. Historically, diagnostic criteria used for human multiple myeloma have been applied to the cat, with the assumption that feline MRD commonly arises in the intramedullary compartment. Our objectives were to describe the features of feline MRD confirmed by cytology, histopathology, histochemistry, and immunohistochemistry and to categorize these tumors. A priori hypotheses were 1) tumor category predicts survival and 2) cats with well-differentiated tumors commonly have extramedullary involvement in contrast to human myeloma patients. This multicenter, retrospective study identified 26 MRD cases. There was good agreement between histopathologic and cytologic tumor categorization. Histochemistry and immunohistochemistry were shown to be valuable adjunct tests in the diagnosis of MRD. Cats with well-differentiated tumors had increased median survival relative to those with poorly differentiated tumors (254 versus 14 days). We have reported that marked extramedullary involvement at initial clinical presentation is significantly more common in the cat than in human MRD patients. In this study, we demonstrate that cats with well-differentiated tumors more commonly have extramedullary involvement than human myeloma patients with well-differentiated tumors (90% versus 20%, P < 0.0002). These results contrast strongly with the human myeloma model of primary intramedullary neoplastic transformation and suggest that primary extramedullary neoplastic transformation may be more common in feline MRD.

Entities:  

Mesh:

Year:  2008        PMID: 18424828     DOI: 10.1354/vp.45-2-159

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  6 in total

1.  Primary duodenal plasmacytoma with associated primary (amyloid light-chain) amyloidosis in a cat.

Authors:  Yu Tamura; James K Chambers; Sakurako Neo; Yuko Goto-Koshino; Satoshi Takagi; Mizuho Uneyama; Kazuyuki Uchida; Masaharu Hisasue
Journal:  JFMS Open Rep       Date:  2020-09-21

2.  Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.

Authors:  Ricardo Fernández; Esther Chon
Journal:  J Vet Intern Med       Date:  2018-03-22       Impact factor: 3.333

3.  Multiple myeloma in an Amur tiger (Panthera tigris altaica).

Authors:  Alison M Lee; Naomi Guppy; John Bainbridge; Hanne Jahns
Journal:  Open Vet J       Date:  2017-10-29

4.  Myeloma-related disorder with leukaemic progression in a cat.

Authors:  Yoshinori Takeuchi; Haruna Iizuka; Hiroyuki Kanemitsu; Yasuhito Fujino; Ko Nakashima; Kazuyuki Uchida; Koichi Ohno; Hiroyuki Nakayama; Hajime Tsujimoto
Journal:  J Feline Med Surg       Date:  2010-10-30       Impact factor: 2.015

5.  Paraneoplastic ganglioradiculoneuritis in a cat with a plasma cell tumour.

Authors:  Oliver Marsh; Alessandra Destri; Stefano Di Palma; Lorenzo Mari; Luisa De Risio; Fabio Stabile
Journal:  JFMS Open Rep       Date:  2021-03-31

6.  Bimodal immunoglobulin A gammopathy in a cat with feline myeloma-related disorders.

Authors:  Masaya Igase; Takako Shimokawa Miyama; Satoshi Kambayashi; Yumiko Shimoyama; Hiroko Hiraoka; Yumi Hirata; Miki Iwata; Kenji Baba; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2015-12-04       Impact factor: 1.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.